GlassScriptPhysician profile
Dolly B Manvar
NPI 1942244942
$3,833.07
in general payments reported to CMS, 2019-2025
18 companies · $576 in 2025
The $576 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $125 · 2021: $547 · 2022: $822 · 2023: $889 · 2024: $624 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,073 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,073.33 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $789.67 | 2021-2025 | |
| Medtronic, INC. | $646.08 | 2022-2025 | Hawkone |
| Shockwave Medical, INC | $347.63 | 2021-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Regeneron Healthcare Solutions, INC. | $322.10 | 2022-2023 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $267.95 | 2022-2024 | Tezspire, Airsupra |
| Amarin Pharma, INC. | $255.60 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $225.54 | 2021-2022 | |
| Glaxosmithkline, LLC. | $222.97 | 2025 | Nucala |
| Optinose US, INC. | $151.17 | 2021-2024 | |
| Amgen INC. | $143.12 | 2022-2023 | Tezspire |
| Bard Peripheral Vascular, INC. | $132.52 | 2023 | Crosser Iq |
| Abbott Laboratories | $114.35 | 2024-2025 | Freestyle Libre 3 |
| Csl Behring | $109.54 | 2019 | |
| Pfizer INC. | $32.25 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $28.79 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $19.17 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $13.83 | 2023 | |
| Genentech USA, INC. | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dolly Manvar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.